NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBYGet Free Report) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets lowered their price target on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a report on Monday, November 11th.

Get Our Latest Report on NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Price Performance

NovaBay Pharmaceuticals stock opened at $0.57 on Friday. NovaBay Pharmaceuticals has a one year low of $0.36 and a one year high of $9.08. The company’s fifty day moving average price is $0.63 and its two-hundred day moving average price is $0.99. The company has a market capitalization of $2.80 million, a price-to-earnings ratio of -0.01 and a beta of 0.69.

About NovaBay Pharmaceuticals

(Get Free Report)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.

Recommended Stories

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.